Advertisment

Exploring the Potential Role of Metformin in Preventing Age-Related Macular Degeneration

author-image
Zara Nwosu
New Update
NULL

Exploring the Potential Role of Metformin in Preventing Age-Related Macular Degeneration

Advertisment

Age-Related Macular Degeneration (AMD) is a significant global health concern, especially in aging populations. A recent case-control study suggests the use of metformin, a commonly used drug for managing type 2 diabetes, could potentially reduce the likelihood of developing AMD among patients without a diabetes diagnosis. However, while the results are promising, they are not conclusive, and more research is needed.

Advertisment

Metformin's Potential Protective Effect Against AMD

Researchers from the University of Chicago used a nationwide insurance claims database to study the potential association between metformin use and AMD. They included more than 231,000 cases with AMD and over 232,000 matched controls without diabetes. After adjusting for known AMD risk factors, the study found that metformin use was linked with a 17% lower odds of developing any AMD. Moreover, this association was not dependent on the dosage, suggesting a potential protective effect of metformin against AMD.

The researchers also found a dose-dependent relationship between metformin use and AMD. Specifically, two-year cumulative metformin doses of 1 to 270 g, 271 to 600 g, and 601 to 1,080 g were associated with 20%, 19%, and 12% lower odds for developing AMD, respectively. Similar trends were observed when focusing on dry AMD, a milder form of the disease compared to wet AMD.

Advertisment

Limitations of the Study

Despite these encouraging findings, the study has some limitations. One major concern is the lack of data on possible confounding factors that could influence the results. Additionally, the potential for coding errors in the claims data used for the study could have affected the findings. Therefore, while the study indicates a possible protective effect of metformin on eye health, it does not provide enough evidence to recommend metformin for AMD prevention at this time.

Further Research Needed

Advertisment

The results of this study support the idea of conducting more randomized trials to further investigate the impact of metformin on AMD prevention. For instance, a cellular AMD model study found that metformin had antioxidative and anti-inflammatory properties in ARPE 19 cells by activating the Nrf2 signaling, which could potentially be used for the control and prevention of AMD.

However, a randomized Phase II clinical trial that aimed to test whether metformin could slow GA progression found no significant effects. The trial included 66 patients aged 55 or older without diabetes and with GA from atrophic AMD in at least one eye. While the safety profile was acceptable, six out of the 32 participants in the metformin group withdrew due to tolerability issues.

These mixed results highlight the complexity of the relationship between metformin and AMD, and the need for more rigorous, randomized trials. Until such research is conducted, it is premature to consider metformin a viable preventative measure against AMD.

Conclusions

While the University of Chicago study offers promising results, it is important to note that more research is needed to fully understand the potential role of metformin in preventing AMD. Healthcare providers should continue to base their AMD prevention strategies on established risk factors until more definitive evidence emerges on the role of metformin in AMD prevention.

Advertisment
Chat with Dr. Medriva !